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OBJECTIVES: In this study, we aimed to investigate
plasma homocysteine (Hcy) and serum C-reactive
protein (CRP) levels in hemodialysis (HD) and con-
tinuous ambulatory peritoneal dialysis (CAPD) pa-
tients, and the relation among them.
Materials and methods: This study was carried out
on 52 HD patients, 26 CAPD patients and a control
group of 22 healthy persons. Blood samples were
taken from the patients for Hcy and CRP measure-
ments.
Results: Serum CRP level was found to be high in
48.1% of HD patients, 69.2% of CAPD patients and
4.5% of the healthy control group. Plasma Hcy level
was found out to be above the normal limits in 73.1%
of HD patients, 65.4% of CAPD patients and 9% of the
healthy control group. There was a significant posi-
tive relation (r /0.384, pB /0.001) between the levels
of plasma Hcy and serum CRP in HD and CAPD
patients.
Conclusion: The high levels of Hcy and CRP were
found out to be higher in HD and CAPD patients than
in the control group. In order to determine the risk
rate of Hcy and CRP for coronary artery disease,
extensive investigations are required in patients with
chronic renal failure that also have coronary artery
disease.
Key words: Homocysteine, C-reactive protein, Hemodia-
lysis, Continuous ambulatory peritoneal dialysis
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Introduction
Cardiovascular diseases are the major reason for
mortality and morbidity of patients with chronic renal
failure.
1 The cardiovascular death rate in hemodia-
lysis (HD) patients is predicted as 9% per year and
those in patients with chronic renal failure are 10-fold
to 20-fold higher than in the normal population.
1,2
It is noteworthy that the risk factors defined for
coronary artery disease such as heredity, hyperten-
sion, diabetes, smoking, and a high level of blood
lipids had been shown even at the earliest stages of
renal failure.
2,3 In recent times the finding of high
serum C-reactive protein (CRP), which is the marker
of both hyperhomocysteinemia and inflammation, is
considered a high risk factor for atherosclerotic
vascular diseases in patients with chronic renal
diseases, but some studies found no association or
only a small association between plasma homocys-
teine (Hcy) levels and cardiovascular disease.
2,4,5
In this study, we aimed to examine the serum
levels of plasma Hcy and serum CRP and the
relationship between CRP, Hcy, and measures of
therapy adequacy (Kt/V, serum albumin) in patients
with chronic renal failure, in HD patients and in
treated continuous ambulatory peritoneal dialysis
(CAPD) patients.
Patients and method
This study was carried on 52 patients (19 female, 33
male) undergoing HD due to the end stage of renal
failure, 26 patients (nine female, 17 male) undergoing
CAPD and 22 healthy persons (eight female, 14 male)
as a control group in our center after gaining their
written approval.
Seven HD patients and four CAPD patients of 11
patients had previously diagnosed coronary artery
disease (five of them had a coronary by-pass opera-
tion and six of them were having medical treatment).
Blood samples for urea, creatinine, total choles-
terol, high-density lipoprotein (HDL)-cholesterol,
low-density lipoprotein (LDL)-cholesterol, triglycer-
ide, total protein, albumin, CRP, and Hcy levels were
taken from the subjects in the morning after 12 h of
fasting. The subjects were also evaluated for body
mass index (BMI), dialysis time, dialysate volume and
adequacy of dialysis (Kt/V). In addition to these, the
difference between the groups and the relationship
between CRP and Hcy levels and the other para-
meters were assessed.
Ambulatory HD patients were hemodialyzed
on hollow-fiber polysulfone membrane dialysators
with a 1.2 m
2 surface area (Hemoflow F5 and
Polysulfon UF 4.0; Fresenius, Germany) with bicar-
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361bonate containing solutions two or three times
weekly for 4 h.
Peritoneal dialysis solutions of 2/2.5 l with 1.36%,
and when necessary 3.86%, glucose were used three
or four times a day by the patients using CAPD. All
patients ate a chronic renal failure diet and the
control group was fed the normal diet.
The serum urea (10/50 mg/dl), creatinine
(0.8/1.2 mg/dl), total cholesterol (0/200 mg/dl),
HDL-cholesterol (40/80 mg/dl), LDL-cholesterol
(50/160 mg/dl), triglyceride (0/200 mg/dl), total
protein (6.4/8.3 g/dl) and albumin (3.5/5 g/dl)
levels were studied at the central laboratory. The
serum CRP level was measured on a Behring
BN100 (Behring, Marburg, Germany) that uses the
nepholometric method; plasma homocysteine was
assessed by the fluorescense polarization immunoas-
say (Abbott IMX Instruments, Chicago, IL,
USA) method. Three samples for serum CRP
and Hcy levels were obtained from each
patient over a 1-week to 2-week period. The values
of CRP were considered normal when B /0.8 mg/dl,
and the value of Hcy was considered normal when
B /15 mmol/l.
For BMI, the formula of body weight (kg)/height
(m
2) was used.
The adequacy of dialysis (Kt/V) was calculated
with the Kt/V (Jindal) /(0.04 /PRU) /1.2 and
Kt/V (Daurgidas) /ln(R /0.03 /0.75 /UF/W) formu-
las.
The Kt value in CAPD is the 24-h dialysate output
(DV): DV /0.23 /IBW /(2.7 /1.44 /Cr), where
IBW is the ideal body weight and Cr is the residual
renal clearance (l/day).
The possibility of infection was investigated
in subjects whose CRP levels were high, by
determining the erythrocyte sedimentation rate
and the presence or absence of leucocytosis.
Blood samples for CRP were retaken from
patients with an infection 21 days after appropriate
treatment.
Statistical analysis
Results are expressed as mean9 /standard deviation.
Statistical comparisons were evaluated by computer
using the Statistical Package for Social Science for
Windows, version 9.0, system (Release 9.0.0 Standard
version, Copyright SPSS Inc., 1989/1999).
Values between groups were compared using
one-sided analysis of variance, and significant differ-
ences were analyzed using Student’s t-test. The
relationship between serum CRP and Hcy levels
and the other factors, was determined by Pearson’s
correlation test. pB /0.05 was considered statistically
significant.
Results
Of the 52 HD subjects included in this study, eight
were applied HD twice a week and 44 subjects were
applied HD for 4 h three times a week. The mean age
of the subjects was 46.69 /14.8 years (age range, 22/
64 years) and the mean HD time was 29.59 /11
months (range, 9/48 months). Four of the 24 CAPD
subjects had three exchanges and 22 of them had
four exchanges of 2/2.5 l/day, and the mean age
among them was 44.69 /13.5 years (age range, 20/57
years) and the mean CAPD time was 18.39 /10
months (range, 8/42 months). The mean age in the
healthy control group was 45.59 /15.8 years (age
range, 24/62 years). The etiologies of the chronic
renal disease in the studied subjects are presented in
Table 1. The age, gender, BMI, dialysis period, total
serum cholesterol, HDL-cholesterol, LDL-cholesterol,
triglyceride, total protein, albumin, C-reactive pro-
tein, Hcy, dialysate output and mean Kt/V values and
the results of the statistical analysis are presented in
Table 2.
The mean serum CRP level was found to be
89 /4.5 mg/dl in the HD patients, 12.89 /9.7 mg/dl in
the CAPD patients and 0.39 /0.5 mg/dl in the control
group. High serum CRP levels were found in 25 of
the HD subjects (48.1%), 16 of the CAPD subjects
(77.7%) and in one member of the healthy control
group (4.5%). In the HD and CAPD subjects, no
significant relationship could be found between the
CRP levels and the age, gender, BMI, dialysis time,
total cholesterol, HDL-cholesterol, LDL-cholesterol
and total protein values (p  /0.05). In the HD subjects
a negative relationship was present between the
serum CRP level and the Kt/V ratios (r / /0.436,
pB /0.05), and albumin levels (r / /0.325,
pB /0.001). In the CAPD patients there was a negative
relationship between the serum CRP levels and the
dialysate volume (r / /0.265, pB /0.001), and the
albumin values (r / /0.462, pB /0.05).
The mean serum Hcy level was found to be
32.59 /14.3 mmol/l in HD patients, 30.49 /18.7 mmol/l
in CAPD patients and 13.249 /5.26 mmol/l in the
control group. The serum total Hcy level was above
the normal limits in 38 of HD cases (73.1%), 17 of
Table 1. The primary diseases of the patients
Primary disease Hemodialysis Peritoneal
dialysis
Diabetic nephropathy 12 7
Chronic glomerulonephritis 10 4
Hypertensive nephropathy 5 3
Chronic pyelonephritis 4 2
Obstructive nephropathy 4 2
Polycystic renal disease 6 /
Amyloidosis 2 2
Etiology is not known 9 6
Total 52 26
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group cases (9%). It was found to be higher than 100
mmol/l in eight of the HD patients and four of the
CAPD patients.
Hcy levels were found to be high in 21 of 25 HD
subjects and in 13 of 16 CAPD subjects whose CRP
levels were also high. There was a significant positive
relation between the serum Hcy levels and serum
CRP levels in HD and CAPD subjects (r /0.384,
pB /0.001).
Regarding the 11 patients with coronary artery
disease, Hcy levels were found to be high in seven of
them and CRP levels were found to be high in five of
them and, CRP and Hcy levels together were found to
be high in four of them. CRP and Hcy levels were
found to be normal in one patient. The Hcy level was
above 100 mmol/l in five patients.
Discussion
The deaths associated with the end-stage renal
disease occur as a result of the fatal cardiovascular
diseases rather than the direct sequels of uremia, with
the exception of poorly developed countries where
the deaths associated with this condition also occur
as a result of the direct sequels of uremia. Further-
more, the excessive cardiovascular risk has been
detected even in the early stages of the renal failure
and it persists even after the renal transplantation
with a certain high level.
14 The coronary lesion
prevalence was shown to be high in the patients with
renal disease both by the autopsy reports
6 and the
angiographic studies.
7 In recent studies it was shown
that, as an indicator of chronic inflammation, the pro-
inflammatory cytokines and CRP levels were in-
creased in chronic renal failure, and it is thought
that this may be an independent risk factor that may
cause progressive atherosclerosis.
25,8 In these stu-
dies, it was seen that the serum CRP levels were
significantly increased in the subjects who were
treated with HD and peritoneal dialysis.
In cases prior to dialysis, the levels of serum CRP,
an acute phase protein, were found to be related to
the increase in the intima-media surface of the arteria
carotis,
9 other positive and negative acute phase
reactants such as albumin, fibrinogen apolipoprotein
A-1 and lipoprotein (a), serum amyloid A levels were
in correlation with CRP, and some of these proteins
may be additional predictor and/or reasonal factors
considering the high cardiovascular risk in both HD
and peritoneal dialysis patients.
2,3,5,9
In this study the serum CRP levels were found high
in 48.1% of the HD patients, in 69.2% of the CAPD
patients and in 5% of the healthy control group
patients. No significant relationship could be de-
tected between the serum CRP levels and the age,
gender, BMI, dialysis time, total cholesterol, HDL-
cholesterol, LDL-cholesterol and total protein values
in the HD and CAPD subjects. In the HD subjects a
negative relationship was detected between the CRP
levels and the Kt/V ratios and the albumin, and there
was a negative relationship between the serum CRP
level and the dialysate volume and the albumin level
in the CAPD subjects.
Zimmermann et al.
4 reported that the increase in
the CRP levels was 46% in the hemodialysis patients.
Owen and Lowrie
10 reported that this increase was
35%. The reason why the ratio of the CRP increase is
high in the CAPD group is probably that the
inflammation in the CAPD patient can be exaggerated
both by the peritoneal irritation and the decrease in
the removal of the cytokines because of the decrease












Age (years) 46.69 /14.8 44.69 /13.5 45.59 /15.8 Not significant
a,b,c
Gender (female/male)* 19/33 9/17 8/14 Not significant
a,b,c
BMI (kg/m
2) 23.89 /3.6 249 /3.8 24.19 /4 Not significant
a,b,c
Dialysis time (months) 38.39 /15 17.39 /10 / B /0.001
a
Total cholesterol (mg/dl) 1729 /31 2139 /35 1669 /32 B /0.05
c
HDL-cholesterol (mg/dl) 329 /93 5 9 /83 8 9 /9 Not significant
a,b,c
LDL-cholesterol (mg/dl) 1029 /22 1429 /40 1029 /29 B /0.05
c
Triglyceride (mg/dl) 1329 /92 2229 /120 1379 /97 B /0.05
c
Total protein (g/dl) 6.99 /1.8 7.39 /1.6 8.49 /2 B /0.05
b
Albumin (g/dl) 3.49 /0.6 3.29 /0.6 4.39 /0.6 B /0.05
b,c
Dialysate volume (l) / 9.19 /1 / /
Kt/V 1.29 /0.2 2.29 /0.3 / /
CRP (mg/dl) 89 /4.5 12.89 /9.7 0.39 /0.5 B /0.05
a, B /0.001
b,c
Total Hcy 32.59 /14.3 30.49 /18.7 13.29 /5.3 B /0.001
b,c
Data presented as mean9 /standard deviation, except * number of patients.
aHaemodyalysis versus continuous ambulatory peritoneal dialysis.
bHaemodialysis versus control group.
cContinuous ambulatory peritoneal dialysis versus control group.
Hcy and CRP levels in hemodialysis and CAPD
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11 This was found to be
consistent with the results of our study.
In this study, a negative relationship was detected
between the CRP levels and the Kt/V ratios and the
albumin levels in the HD subjects, while there was
again a negative relationship between the serum CRP
level and the dialysate volume and the albumin levels
in the CAPD subjects. We did not find an explanatory
reason and a comorbid condition about this negative
relationship. In the studies a strong relationship was
found between the serum CRP levels and the serum
albumin level in the HD patients, and also it is
suggested that CRP was an important indicator for
cardiovascular and total mortality.
2,3,5
In meta-analyses, the finding of the plasma Hcy
level as high was proposed as an independent risk
factor for cardiovascular diseases in the general
population.
8 In experimental studies it was shown
that hyperhomocysteinemia led to endothelial cell
damage, muscle cell proliferation, enhanced lipid
oxidation, an increase in thrombocyte aggregation,
modulation of the leukocyte/endothelium interac-
tion and interference with clotting factors.
2,4
Moustapha et al.
12 reported the prevalence of
hyperhomocysteinemia as 90% in HD patients and
as 67% in peritoneal dialysis patients. It is shown that
1% of Hcy that is produced daily by healthy persons
was discharged with the peritoneal liquid of those
undergoing continuous peritoneal dialysis. In addi-
tion, it was shown that there was a relation among
hyperhomocysteinemia and cardiovascular dis-
eases,
13 end-stage renal failure
14 and vascular access
thromboses.
15 In this study the serum Hcy level was
found to be above the normal limits in 73.1% of HD
cases, 65.4% of CAPD cases and 9% of the healthy
control group.
In this study Hcy levels were found to be high in
seven of 11 patients that have coronary artery
disease, CRP levels in five patients, and CRP and
Hcy levels together in four patients. CRP and Hcy
levels were found to be normal in one patient. The
levels of Hcy in five patients were determined higher
than 100 mmol/l.
Finally, in this study it was detected that the serum
CRP levels were higher in the HD and CAPD subjects
when compared with the control group subjects.
Therefore in order to determine the risk rate of Hcy
and CRP regarding coronary artery disease, extensive
research should be carried out on chronic renal
failure patients with coronary artery disease.
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